Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia | Aplastic Anemia & MDS International Foundation
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Clinical Trial: NCT02828592

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.

Status: 
Recruiting
Study Date: 
Mon, 07/11/2016 to Mon, 08/21/2023
Bone Marrow Disease(s): 
  • aplastic anemia
Intervention: 
Drug: Fludarabine 30 mg/m2 IV QD x 5 days (Days -6 to -2) Drug: Cyclophosphamide 14.5 mg/kg/day IV x 2 doses (Days -6 & -5) Radiation: Total Body Irradiation 300 cGy x1 dose (Day -1) Other Name: TBI Drug: Rabbit ATG 1.5 mg/kg/day x 3 days (Days -3 to -1) Drug: Cyclophosphamide Post-transplant: 50 mg/kg IV QD (Day +3 to +4)